Long-lasting response with metronomic capecitabine in advanced hepatocellular carcinoma

Tumori

Volumn 96, Issue 5, 2010, Pages 768-770

  Ballardini, Pierluigi ^a   Marri, Ivan ^a   Margutti, Guido ^a   Aliberti, Camillo ^a   Benea, Giorgio ^a   Manfredini, Roberto ^a  

^a Ospedale del Delta   (Italy)

Author keywords

Hepatocellular carcinoma; Metronomic capecitabine

Indexed keywords

CAPECITABINE; DOXORUBICIN; SORAFENIB;

ABDOMINAL RADIOGRAPHY; ADVANCED CANCER; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CASE REPORT; CHEMOEMBOLIZATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEPATITIS B; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER METASTASIS; LONG TERM CARE; LOW DRUG DOSE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 78650506052     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089161009600521     Document Type: Article

References (19)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer, 94: 153-156, 2001.
2. Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology, 42: 1208-1236, 2005.
3. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet, 362: 1907-1917, 2003.
4. Llovet JM, Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology, 37: 429-442, 2003.
5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane P, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi J, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 359: 378-390, 2008.
6. Carlomagno F, Anaganti S, Guida T, Provitera L, Kjaer S, McDonald NQ, Ryan AJ, Santoro M: BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst, 98: 326-334, 2006. (Pubitemid 43338212)
7. Wilhelm SM, Carte C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G: Trail PA.BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res, 64: 7099-7109, 2004.
8. Llovet JM, Bru C, Bruix J: Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis, 19: 329-338, 1999.
9. Palmer DH, Hussain SA, Johnson PJ: Systemic therapies for hepatocellular carcinoma. Expert Opin Invest Drugs, 13: 1555-1568, 2004.
10. Von Delius S, Lersch C, Mayr M, Stock K, Schulte-Frohlinde E, Schmid RM, Eckel F: Capecitabine for treatment of advanced hepatocellular carcinoma. Hepatogastroenterology, 54: 2310-2314, 2007.
11. Zhang Q, Kang X, Yang B, Wang J, Yang F: Antiangiogenic effect of capecitabine combined with ginsenoside Rg3 on breast cancer in mice. Cancer Biother Radiopharm, 23: 647-653, 2008.
12. Kerbel RS, Kamen BA: The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer, 4: 423-436, 2004.
13. Park ST, Jang JW, Kim GD, Park JA, Hur W, Woo HY, Kim JD, Kwon JH, Yoo CR, Bae SH, Choi JY, Yoon SK: Beneficial effect of metronomic chemotherapy on tumor suppression and survival in a rat model of hepatocellular carcinoma with liver cirrhosis. Cancer Chemother Pharmacol, 65: 1029-37, 2010.
14. Brandi G, Fanello S, Piscaglia F, Falanga A, Bolondi L, Fiori S, Derenzini E, Palassini E, Fedele M, Biasco G: Metronomic capecitabine in advanced patients with hepatocellular carcinoma (HCC): Preliminary results. J Clin Oncol, ASCO Annual Meeting Proc (Post-Meeting edition), 25 (18S): abstract 15163, 2007.
15. Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci G, Nolè F, Peruzzotti G, Robertson C, Orlando L, Cinieri S, de Braud F, Viale G, Goldhirsch A: Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer. Antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol, 13: 73-80, 2002.
16. Colleoni M, Orlando L, Sanna G, Rocca A, Maisonneuve P, Peruzzotti G, Ghisini R, Sandri MT, Zorzino L, Nolè F, Viale G, Goldhirsch A: Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol, 17: 232-238, 2006.
17. Kamat AA, Kim TJ, Landen CN Jr, Lu C, Han LY, Lin YG, Merrit WM, Thaker PH, Gershenson DM, Bischoff FZ, Heymach JV, Jaffe RB, Coleman RL, Sood AK: Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res, 67: 281-288, 2007.
18. Nelius T, Klatte T, de Riesa W, Haynes A, Filleur S: Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cycophosphamide-based metronomic chemotherapy. Med Oncol, 27: 363-367, 2010.
19. Calvani N, Orlando L, Nacci A, Sponziello F, Cinefra M, Cinieri S: Metronomic chemotherapy against cancer: from paradigm to clinical practice? Tumori, 95: 843-845, 2009.